Skip to content
Homepage
Author:
Spectrum Science
Posted Date:
July 8, 2026
Spectrum Science Appoints Industry Veteran Marie Emms as President of Clinical Business
Spectrum Science
July 8, 2026
Apnimed Announces Publication of its Phase 3 SynAIRgy Trial of AD109 for Obstructive Sleep Apnea in the American Journal of Respiratory and Critical Care Medicine
Spectrum Science
May 18, 2026
Apnimed Announces Three Oral Presentations and a Late-breaking Poster at the American Thoracic Society (ATS) 2026 International Conference
Spectrum Science
May 11, 2026
Spectrum Science Appoints Lisa Talbot to Lead Communications Business
Spectrum Science
April 16, 2026
Apnimed Secures Up to $150 Million in Debt Financing with HealthCare Royalty Partners to Support Planned AD109 Commercial Launch
Spectrum Science
April 6, 2026
Apnimed Announces Strategic Monetization of Shionogi-Apnimed Sleep Science (SASS) Joint Venture Stake for $150M and Royalties, Strengthening Focus on its Wholly-Owned OSA Program, AD109
Spectrum Science
March 24, 2026
